Verastem, Inc. (VSTM) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Verastem, Inc. is a late-stage biopharmaceutical company focused on developing therapies for RAS/MAPK-driven cancers. Its lead candidates are avutometinib (RAF/MEK inhibitor) and defactinib (FAK inhibitor). The company is currently awaiting FDA review of a New Drug Application (NDA) for the combination therapy in low-grade serous ovarian cancer (LGSOC).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $10,000 | $0 |
| Net Loss | $(23,967) | $(20,004) | $(66,086) | $(59,999) |
| Net Loss Per Share (Basic/Diluted) | $(0.60) | $(0.75) | $(2.11) | $(2.93) |
| Operating Expenses | $37,030 | $21,309 | $93,366 | $60,945 |
| Cash, Cash Equivalents & Investments | $113,175 | $137,129 | $113,175 | $137,129 |
| Total Debt (Current + Long-term) | $40,517 | $40,086 | $40,517 | $40,086 |
| Warrant Liability | $26,138 | $0 | $26,138 | $0 |
Note: Revenue for the nine months ended Sept 30, 2024, includes a $10 million milestone payment from Secura related to the COPIKTRA license sale.
Material Changes vs. Prior Period
- Operating Expenses: Increased significantly in Q3 2024 ($37.0M) compared to Q3 2023 ($21.3M). This was driven by higher R&D costs ($24.8M vs $13.9M) due to expanded clinical trials (RAMP 301, RAMP 201) and a $3.0M milestone payment to GenFleet. SG&A expenses rose to $12.3M from $7.4M, largely due to $3.0M in financing fees from the July 2024 offering.
- Net Loss: Q3 2024 net loss was $24.0M, an increase from $20.0M in Q3 2023. However, the loss was mitigated by a $13.5M non-cash gain from the change in fair value of warrant liabilities.
- Liquidity: Cash and investments decreased from $137.1M at year-end 2023 to $113.2M at Q3 2024, reflecting operating burn and investment maturities, partially offset by a $50.8M net proceeds from the July 2024 public offering.
- Debt Structure: The company has $40.0M in principal outstanding under its Oxford Finance loan agreement. A $9.9M current portion of long-term debt was reclassified in Q3 2024.
Guidance, Outlook, and Risks
- Regulatory Status: In October 2024 (post-period), Verastem submitted an NDA for avutometinib + defactinib for recurrent KRAS mutant LGSOC under the Accelerated Approval pathway, requesting Priority Review. The FDA did not recommend pursuing accelerated approval for the KRAS wild-type indication at this time.
- Clinical Pipeline: The RAMP 301 Phase 3 confirmatory trial is ongoing. The RAMP 203 trial (avutometinib + LUMAKRAS) is enrolling, while the RAMP 204 trial was closed to enrollment to prioritize RAMP 203.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months following the issuance of these financial statements. The company anticipates continued operating losses and relies on existing cash, potential milestones, and future financing to fund operations.
- Capital Markets: In July 2024, the company completed an offering of common stock and warrants, raising approximately $50.8 million in net proceeds. Warrants issued in this offering are recorded as a liability and subject to fair value adjustments.
Investor Verification Checklist
- Going Concern Assessment: Verify the company's specific plan to secure additional capital to fund operations beyond the next 12 months, given the explicit "substantial doubt" disclosure.
- NDA Review Timeline: Monitor the FDA's acceptance of the NDA for avutometinib + defactinib and the timeline for the Priority Review decision (expected within 6 months of filing).
- Warrant Liability Volatility: Track the fair value of the $26.1M warrant liability, as fluctuations in the stock price will directly impact reported net income/loss.
- Debt Covenants: Review the Oxford Finance loan agreement terms, specifically the milestone triggers for additional drawdowns (Term C, D, E loans) and repayment schedules starting in 2025/2026.
- Secura Milestones: Confirm future potential revenue from the Secura agreement, noting that future milestones are currently constrained and not recognized in revenue.